MARKET

EYES

EYES

Second Sight Med
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.02
-0.10
-1.95%
Closed 16:00 01/17 EST
OPEN
5.11
PREV CLOSE
5.12
HIGH
5.19
LOW
4.929
VOLUME
26.00K
TURNOVER
--
52 WEEK HIGH
9.60
52 WEEK LOW
4.500
MARKET CAP
78.19M
P/E (TTM)
-0.2239
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of EYES and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 2 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

EYES News

  • Can Second Sight Medical Products (NASDAQ:EYES) Afford To Invest In Growth?
  • Simply Wall St..5d ago
  • The Daily Biotech Pulse: Verastem In-Licenses Chughai's Tumor Drug, Midatech Surges On Positive Study Results
  • Benzinga.01/08 13:12
  • The Daily Biotech Pulse: Xeris Jumps On Positive Data, Mixed Results For Merck's Keytruda-Chemo Combo In Lung Cancer, Intra-Cellular Announces Offering
  • Benzinga.01/07 12:57
  • Second Sight (-9%) reverse splits shares 1:8
  • seekingalpha.01/06 21:39

More

Industry

Medical Equipment, Supplies & Distribution
+0.07%
Healthcare Equipment & Supplies
+0.29%

Hot Stocks

Name
Price
%Change

About EYES

Second Sight Medical Products, Inc. is engaged in developing, manufacturing and marketing prosthetic devices that restore vision to blind individuals. The Company intends to develop Orion Visual Cortical Prosthesis which provides useful artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease or forms of cancer and trauma. Its product, The Argus II Retinal Prosthesis System (The Argus II) provides electrical stimulation of the retina to induce visual perception in blind individuals and helps in treating outer retinal degenerations, such as retinitis pigmentosa (RP). The Argus II System provides an artificial form of vision that differs from the vision of people with normal sight. The Company's Argus II System employs electrical stimulation to bypass degenerated photoreceptor cells and to stimulate remaining viable retinal cells thereby inducing visual perception in blind individuals.
More

Webull offers Second Sight Medical Products Inc (EYES) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.